Follow The Filings

XERS Xeris Biopharma Holdings Inc.

Health Care, filed as XERIS BIOPHARMA HOLDINGS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.1%
  • $827K

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 0.11%

Who owns XERS

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 0.11% Hold 104,410 $827K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by XERS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All XERS insider trades
  • None no insider bought on the open market
  • $977K sold by 1 insider outside a trading plan
  • $4.4M sold by 9 insiders under 10b5-1 plans
  1. Steven Pieper See Remarks
    Planned sale
    $47K 5,000 shares at $9.41 0.4% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  2. Kevin McCulloch See Remarks
    Planned sale
    $141K 15,000 shares at $9.41 0.9% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  3. Beth Hecht See Remarks
    Planned sale
    $157K 16,666 shares at $9.41 1.5% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  4. Kevin McCulloch See Remarks
    Planned sale
    $250K 25,000 shares at $10.00 1.5% of stake
    Traded Sep 28 Filed Sep 29
    ↗
  5. Kevin McCulloch See Remarks
    Planned sale
    $127K 15,000 shares at $8.49 0.9% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  6. Steven Pieper See Remarks
    Planned sale
    $43K 5,000 shares at $8.50 0.4% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  7. Beth Hecht See Remarks
    Planned sale
    $141K 16,666 shares at $8.49 1.5% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  8. Steven Pieper See Remarks
    Planned sale
    $43K 5,000 shares at $8.50 0.4% of stake
    Traded Aug 12 Filed Aug 12
    ↗
  9. Kevin McCulloch See Remarks
    Planned sale
    $120K 15,000 shares at $8.02 0.9% of stake
    Traded Aug 3 Filed Aug 4
    ↗
  10. Beth Hecht See Remarks
    Planned sale
    $134K 16,666 shares at $8.01 1.4% of stake
    Traded Aug 3 Filed Aug 4
    ↗
  11. Steven Pieper See Remarks
    Planned sale
    $383K 45,000 shares at $8.52 3.2% of stake
    Traded Jul 6–7 Filed Jul 7
    ↗
  12. Kevin McCulloch See Remarks
    Planned sale
    $723K 90,000 shares at $8.03 5.1% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  13. Beth Hecht See Remarks
    Planned sale
    $134K 16,666 shares at $8.03 1.4% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  14. Marla Persky Director
    Planned sale
    $91K 15,500 shares at $5.90 11% of stake
    Traded Jun 3 Filed Jun 5
    ↗
  15. Dawn Halkuff Director
    Planned sale
    $122K 20,000 shares at $6.09 17% of stake
    Traded Jun 4 Filed Jun 5
    ↗

Also filed in the last 12 months, not counted as buying or selling: 15 share withholdings for taxes, 12 stock grants, and 9 option exercises.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 3.02,8.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 3.02,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $163.91M $203.07M $291.84M
Net income -$62.26M -$54.84M $0.554M
Net margin * -38.0% -27.0% 0.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $156.26M $167.66M $240.31M
Total non-current assets * $166.34M $155.4M $143.21M
Total assets $322.6M $323.06M $383.53M
Total current liabilities $95.19M $100.44M $109.57M
Total non-current liabilities * $234.19M $252.23M $260.26M
Total equity -$6.78M -$29.62M $13.69M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$47.02M -$36.98M $28.63M
Cash from investing -$6M $4.88M -$0.696M
Cash from financing -$1.61M $36.17M $11.39M
Net change in cash -$54.64M $4.07M $39.32M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.